SSC
RLMD icon

Spruce Street Capital’s Relmada Therapeutics RLMD Stock Holding History

Spruce Street Capital’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44.2M Buy
6,391,328
+129,214
+2% +$903K 8.68% 4
2026
Q1 		$43M Buy
6,262,114
+2,175,933
+53% +$10.3M 10.34% 1
2025
Q4 		$19.7M Buy
+4,086,181
New +$13.7M 6.52% 4

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Spruce Street Capital's RLMD Position: Q2 2026 in Review

Spruce Street Capital increased its Relmada Therapeutics (RLMD) stake by 2.1% in Q2 2026, buying an estimated $903K and bringing the position to 6,391,328 shares worth $44.2M. The position accounts for 8.68% of the portfolio, ranked #4.

Spruce Street Capital first reported a position in RLMD in Q4 2025 and has held it in 3 quarters since. 127 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Spruce Street Capital held 6,391,328 shares of Relmada Therapeutics worth $44.2M as of Q2 2026.
  • Spruce Street Capital bought 129,214 Relmada Therapeutics shares in Q2 2026, an estimated $903K.
  • Relmada Therapeutics made up 8.68% of Spruce Street Capital's portfolio in Q2 2026, its #4 holding.
  • Spruce Street Capital first reported a position in Relmada Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 127 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Spruce Street Capital's 13F filing for Q2 2026, filed 13 Aug 2026.